

CITATION REPORT

List of articles citing

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

DOI: 10.1016/j.clgc.2021.10.004
Clinical Genitourinary Cancer, 2021, , .

Source: <https://exaly.com/paper-pdf/91241562/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. <i>Future Oncology</i> ,	3.6	0
2	Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now. 2022 , 23, 1269-1287		3
1	Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint. 2022 , 82, 1649-1662		0